-
Measures facilitate approval of 48 first-in-class innovative drugs
2025-03-21
China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and accelerating patient access to novel therapies, according to a report released on Tuesday by the National Medical Products Administration.
-
China approves 48 innovative drugs in 2024
2025-03-19
China approved 48 first-in-class innovative drugs in 2024, covering nearly 20 therapeutic areas, including oncology, neurological disorders, endocrine diseases and anti-infective medicines, according to a report released by the National Medical Products Administration on Tuesday.
-
Ebronucimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ebronucimab Injection (trade name: 伊喜宁) of Kangrong Dongfang (Guangdong) Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Iparomlimab and Tuvonralimab Injection Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Iparomlimab and Tuvonralimab Injection (trade name: 齐倍安) of Qilu Pharmaceuticals Co., Ltd. is approved for marketing with conditions by China NMPA. It is indicated for the treatment of recurrent or refractory cervix carcinoma patients who progressed on or after platinum-based chemotherapy.
-
Ongericimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ongericimab Injection (trade name: 君适达/Junshida) of Shanghai Junshi Biosciences Co., Ltd. is approved for marketing by China NMPA.
-
Pradefovir Mesylate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Class 1 innovative drug Pradefovir Mesylate Tablets (trade name: 新舒沐) of Xi'an Gelan Xintong Pharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of adult patients with chronic hepatitis B, providing a new treatment option for patients.
